Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4).
Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition. This has resulted in a strong need for better therapeutics such as incretin based drugs. Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells.
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Incretin-based Drugs market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Incretin-based Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Incretin-based Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
GlaxoSmithKline
Johnson & Johnson
Eli Lilly and Company
Sanofi
Novartis
Merck & Co
Boehringer Ingelheim
Takeda Pharmaceutical Company
AstraZeneca
By Type:
Glucagon-like Peptide-1 Receptor (GLP-1) Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By End-User:
Oral Drugs
Injectable Drugs
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Incretin-based Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 USA Incretin-based Drugs Market Size and Growth Rate of Glucagon-like Peptide-1 Receptor (GLP-1) Agonists from 2016 to 2027
-
1.3.2 USA Incretin-based Drugs Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Incretin-based Drugs Market Size and Growth Rate of Oral Drugs from 2016 to 2027
-
1.4.2 USA Incretin-based Drugs Market Size and Growth Rate of Injectable Drugs from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Incretin-based Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Incretin-based Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Glucagon-like Peptide-1 Receptor (GLP-1) Agonists
-
3.4.2 Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
4 Segmentation of Incretin-based Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Incretin-based Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Incretin-based Drugs in Oral Drugs
-
4.4.2 Market Size and Growth Rate of Incretin-based Drugs in Injectable Drugs
5 Market Analysis by Regions
-
5.1 USA Incretin-based Drugs Production Analysis by Regions
-
5.2 USA Incretin-based Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Incretin-based Drugs Landscape Analysis
-
6.1 West USA Incretin-based Drugs Landscape Analysis by Major Types
-
6.2 West USA Incretin-based Drugs Landscape Analysis by Major End-Users
7 South USA Incretin-based Drugs Landscape Analysis
-
7.1 South USA Incretin-based Drugs Landscape Analysis by Major Types
-
7.2 South USA Incretin-based Drugs Landscape Analysis by Major End-Users
8 Middle West USA Incretin-based Drugs Landscape Analysis
-
8.1 Middle West USA Incretin-based Drugs Landscape Analysis by Major Types
-
8.2 Middle West USA Incretin-based Drugs Landscape Analysis by Major End-Users
9 Northeast USA Incretin-based Drugs Landscape Analysis
-
9.1 Northeast USA Incretin-based Drugs Landscape Analysis by Major Types
-
9.2 Northeast USA Incretin-based Drugs Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 GlaxoSmithKline
-
10.1.1 GlaxoSmithKline Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Johnson & Johnson
-
10.2.1 Johnson & Johnson Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 Eli Lilly and Company
-
10.3.1 Eli Lilly and Company Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Sanofi
-
10.4.1 Sanofi Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Novartis
-
10.5.1 Novartis Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
-
10.6 Merck & Co
-
10.6.1 Merck & Co Company Profile and Recent Development
-
10.6.2 Market Performance
-
10.6.3 Product and Service Introduction
-
10.7 Boehringer Ingelheim
-
10.7.1 Boehringer Ingelheim Company Profile and Recent Development
-
10.7.2 Market Performance
-
10.7.3 Product and Service Introduction
-
10.8 Takeda Pharmaceutical Company
-
10.8.1 Takeda Pharmaceutical Company Company Profile and Recent Development
-
10.8.2 Market Performance
-
10.8.3 Product and Service Introduction
-
10.9 AstraZeneca
-
10.9.1 AstraZeneca Company Profile and Recent Development
-
10.9.2 Market Performance
-
10.9.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Incretin-based Drugs Market Size and Growth Rate of Glucagon-like Peptide-1 Receptor (GLP-1) Agonists from 2016 to 2027
-
Figure USA Incretin-based Drugs Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Incretin-based Drugs Market Size and Growth Rate of Oral Drugs from 2016 to 2027
-
Figure USA Incretin-based Drugs Market Size and Growth Rate of Injectable Drugs from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Incretin-based Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Incretin-based Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Incretin-based Drugs
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Incretin-based Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Incretin-based Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Glucagon-like Peptide-1 Receptor (GLP-1) Agonists
-
Figure Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Incretin-based Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Incretin-based Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Oral Drugs
-
Figure Market Size and Growth Rate of Injectable Drugs
-
Table USA Incretin-based Drugs Production by Regions
-
Table USA Incretin-based Drugs Production Share by Regions
-
Figure USA Incretin-based Drugs Production Share by Regions in 2016
-
Figure USA Incretin-based Drugs Production Share by Regions in 2021
-
Figure USA Incretin-based Drugs Production Share by Regions in 2027
-
Table USA Incretin-based Drugs Consumption by Regions
-
Table USA Incretin-based Drugs Consumption Share by Regions
-
Figure USA Incretin-based Drugs Consumption Share by Regions in 2016
-
Figure USA Incretin-based Drugs Consumption Share by Regions in 2021
-
Figure USA Incretin-based Drugs Consumption Share by Regions in 2027
-
Table West USA Incretin-based Drugs Consumption by Types from 2016 to 2027
-
Table West USA Incretin-based Drugs Consumption Share by Types from 2016 to 2027
-
Figure West USA Incretin-based Drugs Consumption Share by Types in 2016
-
Figure West USA Incretin-based Drugs Consumption Share by Types in 2021
-
Figure West USA Incretin-based Drugs Consumption Share by Types in 2027
-
Table West USA Incretin-based Drugs Consumption by End-Users from 2016 to 2027
-
Table West USA Incretin-based Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Incretin-based Drugs Consumption Share by End-Users in 2016
-
Figure West USA Incretin-based Drugs Consumption Share by End-Users in 2021
-
Figure West USA Incretin-based Drugs Consumption Share by End-Users in 2027
-
Table South USA Incretin-based Drugs Consumption by Types from 2016 to 2027
-
Table South USA Incretin-based Drugs Consumption Share by Types from 2016 to 2027
-
Figure South USA Incretin-based Drugs Consumption Share by Types in 2016
-
Figure South USA Incretin-based Drugs Consumption Share by Types in 2021
-
Figure South USA Incretin-based Drugs Consumption Share by Types in 2027
-
Table South USA Incretin-based Drugs Consumption by End-Users from 2016 to 2027
-
Table South USA Incretin-based Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Incretin-based Drugs Consumption Share by End-Users in 2016
-
Figure South USA Incretin-based Drugs Consumption Share by End-Users in 2021
-
Figure South USA Incretin-based Drugs Consumption Share by End-Users in 2027
-
Table Middle West USA Incretin-based Drugs Consumption by Types from 2016 to 2027
-
Table Middle West USA Incretin-based Drugs Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Incretin-based Drugs Consumption Share by Types in 2016
-
Figure Middle West USA Incretin-based Drugs Consumption Share by Types in 2021
-
Figure Middle West USA Incretin-based Drugs Consumption Share by Types in 2027
-
Table Middle West USA Incretin-based Drugs Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Incretin-based Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Incretin-based Drugs Consumption Share by End-Users in 2016
-
Figure Middle West USA Incretin-based Drugs Consumption Share by End-Users in 2021
-
Figure Middle West USA Incretin-based Drugs Consumption Share by End-Users in 2027
-
Table Northeast USA Incretin-based Drugs Consumption by Types from 2016 to 2027
-
Table Northeast USA Incretin-based Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Incretin-based Drugs Consumption Share by Types in 2016
-
Figure Northeast USA Incretin-based Drugs Consumption Share by Types in 2021
-
Figure Northeast USA Incretin-based Drugs Consumption Share by Types in 2027
-
Table Northeast USA Incretin-based Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Incretin-based Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Incretin-based Drugs Consumption Share by End-Users in 2016
-
Figure Northeast USA Incretin-based Drugs Consumption Share by End-Users in 2021
-
Figure Northeast USA Incretin-based Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of GlaxoSmithKline
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline
-
Figure Sales and Growth Rate Analysis of GlaxoSmithKline
-
Figure Revenue and Market Share Analysis of GlaxoSmithKline
-
Table Product and Service Introduction of GlaxoSmithKline
-
Table Company Profile and Development Status of Johnson & Johnson
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson
-
Figure Sales and Growth Rate Analysis of Johnson & Johnson
-
Figure Revenue and Market Share Analysis of Johnson & Johnson
-
Table Product and Service Introduction of Johnson & Johnson
-
Table Company Profile and Development Status of Eli Lilly and Company
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly and Company
-
Figure Sales and Growth Rate Analysis of Eli Lilly and Company
-
Figure Revenue and Market Share Analysis of Eli Lilly and Company
-
Table Product and Service Introduction of Eli Lilly and Company
-
Table Company Profile and Development Status of Sanofi
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi
-
Figure Sales and Growth Rate Analysis of Sanofi
-
Figure Revenue and Market Share Analysis of Sanofi
-
Table Product and Service Introduction of Sanofi
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
Table Company Profile and Development Status of Merck & Co
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck & Co
-
Figure Sales and Growth Rate Analysis of Merck & Co
-
Figure Revenue and Market Share Analysis of Merck & Co
-
Table Product and Service Introduction of Merck & Co
-
Table Company Profile and Development Status of Boehringer Ingelheim
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim
-
Figure Sales and Growth Rate Analysis of Boehringer Ingelheim
-
Figure Revenue and Market Share Analysis of Boehringer Ingelheim
-
Table Product and Service Introduction of Boehringer Ingelheim
-
Table Company Profile and Development Status of Takeda Pharmaceutical Company
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical Company
-
Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical Company
-
Figure Revenue and Market Share Analysis of Takeda Pharmaceutical Company
-
Table Product and Service Introduction of Takeda Pharmaceutical Company
-
Table Company Profile and Development Status of AstraZeneca
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca
-
Figure Sales and Growth Rate Analysis of AstraZeneca
-
Figure Revenue and Market Share Analysis of AstraZeneca
-
Table Product and Service Introduction of AstraZeneca
-
